12:00 AM
 | 
Dec 17, 2007
 |  BioCentury  |  Regulation

Kynapid voting

Kynapid voting

Kynapid voting
FDA's Cardiovascular and Renal Drugs Advisory Committee voted 6-2 to recommend approval of Kynapid vernakalant IV from Astellas (Tokyo:4503) and Cardiome (TSX:COM; CRME) to treat acute...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >